With HCV Pipeline Crowded, Anadys Acquisition Provides Needed Differentiation
Roche today announced acquisition of US based Anadys pharmaceuticals for $230m in cash, which expands its existing Hepatitis C virus franchise. Anadys brings two pipeline candidates, ANA598 -non-nucleoside direct acting antiviral inhibitors (Setrobuvir, PhII, - NS5B inhibitor) and ANA773- Oral small molecule inducer of exogenous interferon (PhI, TLR 7 agonist), the addition of which should allow Roche to pursue interferon free regimen and address the issue of viral resistance. ANA598 seems to be not impacted by viral resistance as it has produced consistent viral response in both treatment naïve and treatment experience patients.
COMPANIES MENTIONED
